Global Pen Needles Market Outlook
Revenue, 2024
$1.9B
Forecast, 2034
$5.6B
CAGR, 2025 - 2034
11.2%
The Pen Needles industry revenue is expected to be around $2.1 billion in 2025 and expected to showcase growth with 11.2% CAGR between 2025 and 2034. The pen needles market has established itself as an essential element for contemporary diabetes treatment and metabolic disease management because of increasing insulin pen usage and GLP 1 Therapy adoption and patient preference for insulin delivery devices over syringes. Pen needles represent 89.3% of total market demand because they serve as essential tools for treating 1 and 2 diabetes and obesity related conditions through insulin Therapy and GLP 1 Therapy. Standard Pen Needles continues to be the primary choice for medical practice and home treatment because it brought $1.67 billion in revenue during 2024 while enjoying full insurance coverage and doctors preference and easy access to all healthcare locations including hospitals and pharmacies and homecare facilities.
Pen needles function as sterile disposable devices which users insert into their insulin pens and other injectable pens to deliver medications through ultra fine gauges and short lengths with bevel technologies and lubrication systems which help patients experience less pain during subcutaneous injections. The main uses of these devices include Insulin Therapy for strict blood sugar management and GLP 1 Therapy for diabetes and obesity treatment as well as growth hormone and fertility medication administration and pen based insulin delivery systems for biologic and specialty drug self administration. The market demand has experienced changes because patients now prefer safety pen needles which include built in sharps protection features and healthcare providers use shorter thinner needles to enhance patient comfort and treatment compliance. The growing adoption of pen based medical treatments across new markets and the transition of chronic disease management from clinics to homecare environments have made pen needles essential for worldwide injectable therapy systems.
Market Key Insights
The Pen Needles market is projected to grow from $1.9 billion in 2024 to $5.6 billion in 2034. This represents a CAGR of 11.2%, reflecting rising demand across Insulin Therapy, GLP-1 Therapy, and Growth Hormone Therapy.
The market leaders B. Braun SE and Novo Nordisk A/S and Becton Dickinson and Company along with other major companies determine the competitive dynamics of this industry.
The Pen Needles market has the United States and China as its leading customer bases which will experience growth at 8.2% to 11.8% CAGR from 2024 to 2030.
The research predicts Brazil, Mexico and Indonesia will experience the most significant market expansion because their compound annual growth rates (CAGR) will reach between 10.8% and 14.0%.
The market for Pen Needles will experience $463 million additional growth through 2030 because of Transition like Patient-Centric Design Evolution.
.The Pen Needles market will experience $3.6 billion growth during 2024-2034 because manufacturers focus on GLP-1 Therapy & Growth Hormone Therapy Application to achieve higher market penetration.
With
rising global diabetes prevalence and expanding home-based insulin therapy are accelerating demand for advanced pen needles, and
Technological innovation in ultra-thin, safety-engineered pen needles improving patient comfort and injection adherence, Pen Needles market to expand 189% between 2024 and 2034.
Opportunities in the Pen Needles
The implementation of strict occupational safety standards throughout European medical facilities has also created a rapid transition from standard pen needles to safety pen needles. Healthcare providers need passive shield systems and automatic retraction functions to decrease the occurrence of unintentional needlestick injuries while minimizing their legal exposure. The market for safety pen needles will expand from 0.26 billion in 2024 to reach 0.60 billion by 2030 while maintaining a 14.69% annual growth rate which will make them the leading segment in pen based injection therapy for hospitals that treat patients with insulin and other chronic injectable drugs.
Growth Opportunities in North America and Asia-Pacific
The North American market for pen needles depends on its high diabetes rates and sophisticated insulin treatment methods which make insulin based diabetes management the leading application but GLP 1 therapy shows increasing adoption because of growing obesity treatment guidelines and excellent insurance coverage for injectable metabolic medications. The company should focus on three main business opportunities which include premium safety pen needles and ultra short and thin gauge insulin pen needles for home healthcare and GLP 1 therapy and growth hormone therapy products that match patient focused self injection and telehealth follow up systems. The market competition between branded and value tier manufacturers has become extremely fierce because companies now use ergonomic pen needle design and pen injector compatibility and secure retail pharmacy supply and additional services like digital adherence tools and training programs to differentiate themselves. The market depends on three main regional factors which combine pen injector popularity with vial and syringe usage and medical organizations that endorse early injectable treatment and growing osteoporosis medication use among senior citizens and healthcare services that prefer pen needles with safety features and sharps management capabilities.
The Asia Pacific region supports pen needle expansion because it contains the biggest number of diabetic patients who need insulin treatment for their condition and GLP 1 therapy adoption increases in major cities and pediatric and endocrine centers maintain consistent growth hormone therapy requirements. The main business opportunities exist in two region's which involve switching patients from standard syringes to affordable insulin pen needles and developing additional mid range and budget friendly products with built in safety mechanisms and creating pen needles for osteoporosis treatment and other chronic subcutaneous drug delivery needs in aging populations. The market competition exists between multinational companies which develop new products and domestic companies which maintain their manufacturing operations while local businesses fight for market share through price competition and government procurement contracts. The global brands maintain their market position through their ability to deliver reliable products which match popular insulin pens and their commitment to train medical staff about proper pen needle application and site rotation techniques. The main factors which drive regional development consist of healthcare facility expansion and higher medical insurance payments for diabetes treatment equipment and rising public understanding of pen based insulin delivery advantages over syringes and government backed programs for chronic disease management which promote pen needles as the primary injection method in healthcare facilities at both primary and secondary levels.
Market Dynamics and Supply Chain
01
Driver: Rising global diabetes prevalence and expanding home based insulin therapy are accelerating demand for advanced pen needles
The growing number of diabetes patients because of inactive living and rising obesity rates and older population numbers also creates a larger market for insulin delivery devices which will also increase pen needle usage throughout all market segments. Health organizations now focus on detecting diabetes at an early stage while maintaining strict blood sugar levels which results in patients starting insulin pen treatment during their initial diabetes treatment period and needing to administer insulin more often which leads to higher total needle requirements. The transition toward home based insulin therapy and decentralized diabetes care has also created market demand for user friendly fixed dose insulin pens which work with safe and reliable pen needles for self administration. The development of telemedicine services and remote coaching and digital diabetes programs has also motivated patients to switch from using vial and syringe to pen based subcutaneous injection for their 2 diabetes treatment. The market trends create a strong foundation for diabetes care ecosystems to demand high quality pen needles which provide cost effective solutions.
The development of new needle technology has also brought better results through its thinner gauges and thin wall cannulas and its improved bevel design which decreases the need for force during insertion and decreases the amount of pain patients experience thus improving insulin delivery for people who fear needles and senior citizens. The market now offers pen needles with shorter lengths and enhanced tip structures which enable precise subcutaneous medication delivery while reducing the chances of muscle tissue penetration thus helping patients achieve better blood sugar control and follow their treatment plans. The market for pen needles experienced growth because safety pen needles with built in automatic shielding systems protect users from needlestick injuries in home healthcare and clinical settings. The premium segment of the pen needles market also experiences growth through its unique features which include automatic shielding mechanisms for safety pen needles.
02
Restraint: Rising cost pressures and pricing caps erode margins for pen needles in competitive diabetes care markets
Pen needle sales experience reduced revenue expansion because hospitals and clinics use price ceilings and tender based procurement methods which decrease their average selling prices. The increasing number of diabetes patients throughout major regions does not only translate into higher revenue because of these government controls. Manufacturers avoid investing in premium safety pen needles and ultra fine insulin delivery devices because of high production costs which reduces their ability to differentiate their products and decreases distributor and pharmacy chain interest in selecting their higher value pen needle portfolios thus controlling market demand and profitability levels.
03
Opportunity: Growing GLP 1 and insulin co therapy among obese, aging diabetics fuels premium pen needles adoption worldwide and Expansion of home based diabetes management in emerging Asian markets accelerates demand for convenient standard pen needles
The worldwide pen needle market experiences growth because people now use GLP 1 agonists together with basal insulin to treat 2 diabetes which occurs in obese patients. Standard pen needles need to be designed as ultra thin and low friction devices to help patients with complex chronic regimens who need painless and bruise free insulin delivery systems. The standard segment will expand from 1.67 billion USD in 2024 to reach 3.05 billion USD by 2030 which will drive premium gauge sales for self injection devices at higher rates than the total market expansion in North America and Europe.
The expanding middle class of diabetic patients in emerging Asian economies now prefer to receive their injections through home based pen needles instead of traditional clinic based methods. Standard pen needles experience growing demand because governments support decentralized diabetes care through teleconsultation services. The researchers predict that their worldwide business revenue will increase from 1.67 billion in 2024 to 3.05 billion during the 2030 period while Asia will achieve a 10.6% annual growth rate because of its growing retail and hospital pharmacy network and its expanding home healthcare services which focus on providing easy access to insulin delivery.
04
Challenge: Growing adoption of alternative insulin delivery technologies reduces long term dependence on conventional disposable pen needles
The growing adoption of insulin pumps and patch pumps and GLP 1 therapies with extended duration reduces the need for daily insulin pen administration which results in smaller pen needle unit volumes for established diabetes treatment areas. The growing reimbursement of connected insulin delivery devices and digital diabetes management solutions from payers and health systems requires health systems to adopt new treatment approaches which use complete platform systems thus pen needle manufacturers need to evaluate their production capabilities and pricing methods and their working relationships with endocrinology clinics and homecare providers which will reduce their ability to predict future revenue growth.
Supply Chain Landscape
1
Pen Needles Design
B. Braun SENovo Nordisk A/SBecton Dickinson and Company
2
Drug Device Components
Terumo CorporationYpsomedBecton Dickinson and Company
3
Assembly Packaging
Becton Dickinson and CompanyB. Braun SEYpsomed
4
End-use
diabetes careinsulin deliverysubcutaneous injection therapy
1
Pen Needles Design
B. Braun SENovo Nordisk A/SBecton Dickinson and Company
2
Drug Device Components
Terumo CorporationYpsomedBecton Dickinson and Company
3
Assembly Packaging
Becton Dickinson and CompanyB. Braun SEYpsomed
4
End-use
diabetes careinsulin deliverysubcutaneous injection therapy
Use Cases of Pen Needles in Insulin Therapy & GLP-1 Therapy
Insulin Therapy : The pen needles used in insulin therapy serve as a fundamental tool for diabetes care because they produced $1.52 billion in sales during 2024 and experts predict their market will expand by 10.9% annually between 2025 and 2030 because 1 and 2 patients with insulin needs will perform daily self injections. Standard pen needles rule this application because they match the 86.43% total market share since short thin gauge insulin pen needles provide both precise dosing and dependable performance at affordable costs for patients who need to take subcutaneous injections often. The 13.57% demand for safety pen needles grows in hospital and clinic settings because these needles help protect medical staff from needle stick injuries. Becton Dickinson and Company maintains a strong market position through its extensive range of advanced standard and safety pen needles which combine optimized tip geometry with Novo Nordisk A/S using its integrated pen systems and clinical experience and Ypsomed enhances its position through its high quality pen needles and pharmaceutical partner customization services and B. Braun SE and Terumo Corporation focus on safety oriented designs and their sharpness technologies which help maintain drug delivery precision.
GLP-1 Therapy : The development of GLP 1 therapy as a new market segment for pen needles has become a major revenue source which generated 0.21 billion in 2024 and will continue to grow at 14.4% CAGR until 2030 because GLP 1 agonists serve dual purposes for blood sugar management and weight loss. The region requires standard pen needles which connect to prefilled GLP 1 pens for most injection procedures because they offer users simple operation and allow them to inject in hidden region's with exact subcutaneous placement. Safety pen needles become more important for specialty clinics which treat numerous patients because these facilities need better protection for their staff members. The company Novo Nordisk A/S drives this application through its complete GLP 1 product range and its proprietary injection systems which establish industry standards for user friendly design and BD and Ypsomed join the system with their pen needles which improve the complete drug delivery system functionality and Terumo Corporation and B. Braun SE compete through their high performance pen needles with fine gauge design and lubrication and ergonomic shape which helps patients follow their treatment plans.
Growth Hormone Therapy : Pen needles serve as medical tools which healthcare professionals use to treat endocrine disorders through growth hormone therapy. The market for pen needles in growth hormone therapy shows rapid growth because it generated 0.10 billion dollars in 2024 and experts predict it will expand at 12.6% annually from 2025 to 2030 because doctors now diagnose more cases of growth disorders in children and adults. The application uses standard pen needles as the main choice because healthcare providers select short ultra fine needles to achieve maximum patient comfort and minimize anxiety during injections for children and teenagers. The application uses safety pen needles only in home care and training programs which need caregivers to have extra protection and injection confidence during multiple needle procedures. The company Ypsomed maintains its market leadership through its dedication to developing growth hormone delivery systems and individualized pen injection devices. Novo Nordisk A/S maintains its position in the market through its complete hormone therapy devices and its comprehensive clinical support services. The standard and safety pen needles from BD feature precision engineering which helps patients achieve better dosing accuracy. B. Braun SE and Terumo Corporation maintain their market position through their advanced manufacturing techniques and their ability to produce precise bevel designs and their worldwide distribution network which provides hospitals and specialty clinics and home care settings with dependable product access.
Recent Developments
The development of pen needles follows the increasing need for safer insulin delivery systems which people can use easily because diabetes cases continue to rise and patients take more responsibility for their health. The market has seen manufacturers introduce two news of pen needles which include ultra fine painless pen needles and safety pen needles to enhance patient comfort during treatment and improve their ability to follow their medication plans. The market now accepts shorter needles which combine with ergonomic design and work with popular insulin pens. The market shows growing demand for disposable pen needles which manufacturers produce to support homecare and telehealth services in developing countries.
January 2024 : The American Diabetes Association published its 2024 Standards of Care in Diabetes 2024 which provides complete instructions about insulin delivery devices including insulin pens and disposable pen needles and supports healthcare providers to follow optimal subcutaneous injection methods for diabetes treatment.
March 2023 : The European Union passed an amendment which extended the Medical Device Regulation transition period for all legacy medical devices including pen needles to help manufacturers meet upcoming requirements without losing their commitment to high product standards. The amendment provides manufacturers with temporary relief from compliance requirements which enables them to enhance their manufacturing capabilities for insulin delivery devices and maintain pen needle availability throughout Europe for diabetes management needs.
Impact of Industry Transitions on the Pen Needles Market
As a core segment of the Medical Device industry,
the Pen Needles market develops in line with broader industry shifts.
Over recent years, transitions such as Patient Centric Design Evolution and Rise of Connected Delivery have redefined priorities
across the Medical Device sector,
influencing how the Pen Needles market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Patient Centric Design Evolution
The Pen Needles market is undergoing a significant transformation driven by the evolution towards patient centric designs, enhancing diabetes management and biologic medication delivery. This shift is characterized by the development of thinner, more comfortable needles that facilitate adherence to treatment plans for insulin and GLP 1 injections. As healthcare transitions from clinics to home settings, pharmacies are increasingly assuming chronic disease management roles, necessitating a change in procurement practices. The rising demand for safety pen needles with automatic shielding is addressing occupational health concerns by reducing needle stick injuries in healthcare environments. This strategic transition is projected to contribute an additional $463 million in market growth by 2030, underscoring the critical importance of innovation in meeting patient needs and improving healthcare delivery efficiency.
02
Rise of Connected Delivery
The digital revolution has transformed pen needles through their connection to smart insulin pens and dose tracking apps and cloud based diabetes management platforms. The system enables healthcare providers to monitor injection techniques and both injection frequency and any missed doses which helps them create individualized diabetes treatment plans. Pharmaceutical businesses together with device manufacturers have started to create strategic alliances which combine connected pen needles with biologic therapies to create new value streams through data based services instead of traditional single use hardware products. Real world injection data now serves as the foundation which telehealth providers and payers and pharmacy chains use to create their outcomes based reimbursement models.